UB Paderborn / Katalog / Suche / in CDI

In vitro Activity of Ceftaroline Against Isolates of Gram-Positive Bacteria from Patients with Bloodstream Infections Collected as a Part of ATLAS Between 2017 and 2020

Infection and drug resistance, 2024-01, Vol.17, p.343-354

2024

Volltextzugriff (PDF)

In vitro activity of aztreonam-avibactam and comparators against Metallo-β-Lactamase-producing Enterobacterales from ATLAS Global Surveillance Program, 2016–2020

Journal of global antimicrobial resistance., 2024-03, Vol.36, p.123-131

2024

Volltextzugriff (PDF)

In vitro activity of aztreonam/avibactam against isolates of Enterobacterales collected globally from ATLAS in 2019

Journal of global antimicrobial resistance., 2022-09, Vol.30, p.214-221

2022

Volltextzugriff (PDF)

Evaluation of Dilution Susceptibility Testing Methods for Aztreonam in Combination with Avibactam against Enterobacterales

Microbiology spectrum, 2022-12, Vol.10 (6), p.e0360122-e0360122

2022

Volltextzugriff (PDF)

Oritavancin Kills Stationary-Phase and Biofilm Staphylococcus aureus Cells In Vitro

Antimicrobial Agents and Chemotherapy, 2009-03, Vol.53 (3), p.918-925

2009

Volltextzugriff (PDF)

Time–kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium

Journal of antimicrobial chemotherapy, 2009-06, Vol.63 (6), p.1191-1199

2009

Volltextzugriff (PDF)

Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012–2017

Journal of global antimicrobial resistance., 2021-03, Vol.24, p.316-320

2021

Volltextzugriff (PDF)

Ceftazidime-avibactam activity against Gram-negative respiratory isolates collected between 2018 and 2019

Journal of global antimicrobial resistance., 2022-12, Vol.31, p.239-247

2022

Volltextzugriff (PDF)

Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Enterobacterales Analyzed by ICU and Non-ICU Wards, Infection Sources, and Geographic Regions: ATLAS Program 2016–2020

Antibiotics (Basel), 2023-11, Vol.12 (11), p.1591

2023

Volltextzugriff (PDF)

Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin-Resistant Enterococci To Effect Rapid Bacterial Killing

Antimicrobial Agents and Chemotherapy, 2010-12, Vol.54 (12), p.5369-5371

2010

Volltextzugriff (PDF)

Pharmacodynamics of a Simulated Single 1,200-Milligram Dose of Oritavancin in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Methicillin-Resistant Staphylococcus aureus Infection

Antimicrobial Agents and Chemotherapy, 2013-01, Vol.57 (1), p.205-211

2013

Volltextzugriff (PDF)

Effect of Polysorbate 80 on Oritavancin Binding to Plastic Surfaces: Implications for Susceptibility Testing

Antimicrobial Agents and Chemotherapy, 2008-05, Vol.52 (5), p.1597-1603

2008

Volltextzugriff (PDF)

Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model

Antimicrobial agents and chemotherapy, 2018-01, Vol.62 (1)

2018

Volltextzugriff (PDF)

Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates

Antimicrobial Agents and Chemotherapy, 2009-11, Vol.53 (11), p.4762-4771

2009

Volltextzugriff (PDF)

Efficacy of Oritavancin in a Murine Model of Bacillus anthracis Spore Inhalation Anthrax

Antimicrobial Agents and Chemotherapy, 2008-09, Vol.52 (9), p.3350-3357

2008

Volltextzugriff (PDF)

Assessment by Time-Kill Methodology of the Synergistic Effects of Oritavancin in Combination with Other Antimicrobial Agents against Staphylococcus aureus

Antimicrobial Agents and Chemotherapy, 2008-10, Vol.52 (10), p.3820-3822

2008

Volltextzugriff (PDF)

Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin

Journal of antimicrobial chemotherapy, 2009-10, Vol.64 (4), p.868-870

2009

Volltextzugriff (PDF)

Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019

Journal of antimicrobial chemotherapy, 2021-10, Vol.76 (11), p.2833-2838

2021

Volltextzugriff (PDF)

Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection

Antimicrobial agents and chemotherapy, 2017-10, Vol.61 (10)

2017

Volltextzugriff (PDF)

In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci

Diagnostic microbiology and infectious disease, 2017-10, Vol.89 (2), p.168-171

2017

Volltextzugriff (PDF)

In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene

International journal of antimicrobial agents, 2014-07, Vol.44 (1), p.65-68

2014

Volltextzugriff (PDF)

Assessment of Oritavancin Serum Protein Binding across Species

Antimicrobial Agents and Chemotherapy, 2010-08, Vol.54 (8), p.3481-3483

2010

Volltextzugriff (PDF)

In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011–2014

International journal of antimicrobial agents, 2015-12, Vol.46 (6), p.674-681

2015

Volltextzugriff (PDF)

Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus

Diagnostic microbiology and infectious disease, 2017-02, Vol.87 (2), p.121-128

2017

Volltextzugriff (PDF)

Inhibition of Transcription in Staphylococcus aureus by a Primary Sigma Factor-Binding Polypeptide from Phage G1

Journal of Bacteriology, 2009-06, Vol.191 (12), p.3763-3771

2009

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

In vitro Activity of Ceftaroline Against Isolates of Gram-Positive Bacteria from Patients with Bloodstream Infections Collected as a Part of ATLAS Between 2017 and 2020

In vitro activity of aztreonam-avibactam and comparators against Metallo-β-Lactamase-producing Enterobacterales from ATLAS Global Surveillance Program, 2016–2020

In vitro activity of aztreonam/avibactam against isolates of Enterobacterales collected globally from ATLAS in 2019

Evaluation of Dilution Susceptibility Testing Methods for Aztreonam in Combination with Avibactam against Enterobacterales

Oritavancin Kills Stationary-Phase and Biofilm Staphylococcus aureus Cells In Vitro

Time–kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium

Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012–2017

Ceftazidime-avibactam activity against Gram-negative respiratory isolates collected between 2018 and 2019

Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Enterobacterales Analyzed by ICU and Non-ICU Wards, Infection Sources, and Geographic Regions: ATLAS Program 2016–2020

Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin-Resistant Enterococci To Effect Rapid Bacterial Killing

Pharmacodynamics of a Simulated Single 1,200-Milligram Dose of Oritavancin in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Methicillin-Resistant Staphylococcus aureus Infection

Effect of Polysorbate 80 on Oritavancin Binding to Plastic Surfaces: Implications for Susceptibility Testing

Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model

Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates

Efficacy of Oritavancin in a Murine Model of Bacillus anthracis Spore Inhalation Anthrax

Assessment by Time-Kill Methodology of the Synergistic Effects of Oritavancin in Combination with Other Antimicrobial Agents against Staphylococcus aureus

Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin

Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019

Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection

In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci

In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene

Assessment of Oritavancin Serum Protein Binding across Species

In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011–2014

Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus

Inhibition of Transcription in Staphylococcus aureus by a Primary Sigma Factor-Binding Polypeptide from Phage G1

Suchergebnisse filtern